RT Journal Article
SR Electronic
T1 The operational impact of deploying SARS-CoV-2 vaccines in countries of the WHO African Region
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.13.20147595
DO 10.1101/2020.08.13.20147595
A1 Ortiz, Justin R.
A1 Robertson, Joanie
A1 Hsu, Jui-Shan
A1 Yu, Stephen L.
A1 Driscoll, Amanda J.
A1 Williams, Sarah R.
A1 Chen, Wilbur H.
A1 Fitzpatrick, Meagan C.
A1 Sow, Samba
A1 Biellik, Robin J.
A1 Okwo-Bele, Jean-Marie
A1 Neuzil, Kathleen M.
YR 2020
UL http://medrxiv.org/content/early/2020/11/01/2020.08.13.20147595.abstract
AB Background When available, SARS-CoV-2 vaccines will be deployed to countries with limited immunization systems.Methods We conducted an immunization capacity assessment of a simulated WHO African Region country using region-specific data on immunization, population, healthcare workers (HCWs), vaccine cold storage capacity (quartile values for national and subnational levels), and characteristics of influenza vaccines to represent future SARS-CoV-2 vaccines. We calculated monthly increases in vaccine doses, doses per vaccinator, and cold storage volumes for four-month SARS-CoV-2 vaccination campaigns targeting risk groups compared to routine immunization baselines.Findings Administering SARS-CoV-2 vaccines to risk groups would increase total monthly doses by 27.0% for ≥65 years, 91.7% for chronic diseases patients, and 1.1% for HCWs. Assuming median nurse density estimates adjusted for absenteeism and proportion providing immunization services, SARS-CoV-2 vaccination campaigns would increase total monthly doses per vaccinator by 29.3% for ≥65 years, 99.6% for chronic diseases patients, and 1.2% for HCWs. When we applied quartiles of actual African Region country vaccine storage capacity, routine immunization vaccine volumes exceeded national-level storage capacity for at least 75% of countries, but subnational levels had sufficient storage capacity for SARS-CoV-2 vaccines for at least 75% of countries.Interpretation In the WHO African Region, SARS-CoV-2 vaccination campaigns would substantially increase doses per vaccinator and cold chain capacity requirements over routine immunization baselines. Pandemic vaccination campaigns would add volume to national-level stores already at their limits, but sufficient capacity exists at subnational levels. Immediate attention to strengthening immunization systems is essential to support pandemic responses.Funding NoneCompeting Interest StatementJustin R. Ortiz reports that his institution has received grants from Pfizer and NIH for trials of COVID vaccines. Joanie Robertson reports that her organization has received grants from the Bill & Melinda Gates Foundation and from Gavi, the Vaccine Alliance for supply chain research and technical assistance. Jui-Shan Hsu reports that her organization has received grants from the Bill & Melinda Gates Foundation and from Gavi, the Vaccine Alliance for supply chain research and technical assistance. Stephen L. Yu reports no interests. Amanda J. Driscoll reports no interests. Sarah R. Williams reports no interests. Wilbur H. Chen reports he has received research grants from GlaxoSmithKline, Emergent BioSolutions, Institut Pasteur, PATH, Wellcome Trust, and National Institutes of Health for non-SARS-CoV-2 vaccine research. He has received fees from FluGen, Inc., MassBiologics, Pharmaron, Sanaria, Inc., Lumen Bioscience, Inc., and Sequiris for non-SARS-CoV-2 consulting. Meagan Fitzpatrick reports that her institution has received research funding from the National Institutes of Health, PATH, and the Bill & Melinda Gates Foundation, and that she has received consulting fees from Sanofi Pasteur, unrelated to SARS-CoV-2 vaccines. Samba Sow reports no interests. Robin J. Biellik reports no interests. Jean-Marie Okwo-Bele reports no interests. Kathleen M. Neuzil reports that she has received grants from Pfizer and NIH for trials of COVID vaccines. Funding StatementThis work had no specific funding support.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:As there was no involvement of human participants or personal identifiable information, institutional review board approval was not required.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesOur analysis can be replicated fully with methods and data from the study manuscript and supplement and other publicly available data which we have cited. No individual participant data were used. Other study data or documents are not available.